InterventionsHuman trial

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orforglipron: A Multiple Dose Titration Study in Chinese Participants with Obesity or Overweight with Weight-Related Comorbidities

ADA Scientific Sessions 2026 Abstract

The paper

Hui Liu, Ping Feng, Ding Xueying,

钟诗龙, Xiao Ling Du, Haoxin Zhuang, Xiaosu Ma, Shobha Bhattachar,

Chengdu

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 2624-P

doi.org/10.2337/db26-2624-p

Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026